Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.58 |
| ▸ | CA2 | P00918 | 7/20 | 0.58 |
| ▸ | CA12 | O43570 | 6/20 | 0.58 |
| ▸ | CA9 | Q16790 | 6/20 | 0.58 |
| ▸ | KIF11 | P52732 | 9/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | GCK | P35557 | 1/20 | 0.44 |
| ▸ | GCKR | Q14397 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18118193 | 0.83 | CA1 (0.58) | CA1CA2CA12CA9NPC1 | |
| SCHEMBL3253299 | 0.83 | KIF11 (0.42) | CA1CA2CA12CA9KIF11 | |
| SCHEMBL5726849 | 0.83 | GCK (0.44) | CA1CA2CA12CA9KIF11 | |
| SCHEMBL7347511 | 0.83 | KIF11 (0.42) | CA1CA2CA12CA9KIF11 | |
| SCHEMBL14569177 | 0.83 | KIF11 (0.46) | CA1CA2CA12CA9KIF11 | |
| SCHEMBL7055780 | 0.82 | GCK (0.43) | CA1CA2CA12CA9KIF11 | |
| SCHEMBL7055779 | 0.82 | KIF11 (0.45) | CA1CA2CA12CA9KIF11 | |
| SCHEMBL18118201 | 0.81 | CA1 (0.56) | CA1CA2CA12CA9NPC1 | |
| SCHEMBL3563618 | 0.81 | CA12 (0.47) | CA1CA2CA12CA9NPC1 | |
| SCHEMBL3559908 | 0.81 | CA12 (0.50) | CA1CA2CA12CA9KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402966-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2022-12-22 | — | — | US | disclosed |
| US-11040998-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3277286-B1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2021-04-21 | — | — | EP | disclosed |
| US-20200109164-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2020-04-09 | — | — | US | disclosed |
| US-10457703-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| WO-2016161003-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHAMRACEUTICALS, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160289262-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160289262-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2016-10-06 | — | — | US | disclosed |
| WO-2009096198-A1 | NOVEL BIARYL DERIVATIVE | PHARMA IP LIMITED LIABILITY INTERMEDIARY CORPORATIONS (JP) | 2009-08-06 | — | — | WO | disclosed |
| WO-2005005382-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040998-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | CA1 1773/4885CA2 1361/4885CA12 2446/4885 |
| US-20220402966-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | GPBAR1, NR1H4, SLC10A1 | CA1 1773/4885CA2 1361/4885CA12 2446/4885 |
| US-20160289262-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | GPBAR1, NR1H4, SLC10A1 | CA1 1773/4885CA2 1361/4885CA12 2446/4885 |
| US-20200109164-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | GPBAR1, NR1H4, SLC10A1 | CA1 1773/4885CA2 1361/4885CA12 2446/4885 |
| US-10457703-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | CA1 1773/4885CA2 1361/4885CA12 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.